Cancer Research Annual Meeting 2010  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 593, January 15, 2007. doi: 10.1158/0008-5472.CAN-06-3567
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laakkonen, P.
Right arrow Articles by Alitalo, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laakkonen, P.
Right arrow Articles by Alitalo, K.

Cell, Tumor, and Stem Cell Biology

Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth

Pirjo Laakkonen1, Marika Waltari1, Tanja Holopainen1, Takashi Takahashi3, Bronislaw Pytowski2, Philipp Steiner2, Daniel Hicklin2, Kris Persaud2, James R. Tonra2, Larry Witte2 and Kari Alitalo1

1 Molecular/Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland; 2 ImClone Systems, New York, New York; and 3 Division of Molecular Carcinogenesis, Center for Nuerological Disease and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan

Requests for reprints: Kari Alitalo, Molecular/Cancer Biology Research Program and Ludwig Institute for Cancer Research, Biomedicum Helsinki, Haartman Institute and Helsinki University Central Hospital, P.O. Box 63, Haartmaninkatu 8, FI-00014 Helsinki, Finland. Phone: 358-9-191-25511; Fax: 358-9-191-25510; E-mail: kari.alitalo{at}helsinki.fi.

Vascular endothelial growth factor receptor 3 (VEGFR-3) binds VEGF-C and VEGF-D and is essential for the development of the lymphatic vasculature. Experimental tumors that overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and show enhanced metastasis to regional lymph nodes and beyond, whereas a soluble form of VEGFR-3 that blocks receptor signaling inhibits these changes and metastasis. Because VEGFR-3 is also essential for the early blood vessel development in embryos and is up-regulated in tumor angiogenesis, we wanted to determine if an antibody targeting the receptor that interferes with VEGFR-3 ligand binding can inhibit primary tumor growth. Our results show that antibody interference with VEGFR-3 function can inhibit the growth of several human tumor xenografts in immunocompromised mice. Immunohistochemical analysis showed that the blood vessel density of anti-VEGFR-3–treated tumors was significantly decreased and hypoxic and necrotic tumor tissue was increased when compared with tumors treated with control antibody, indicating that blocking of the VEGFR-3 pathway inhibits angiogenesis in these tumors. As expected, the anti-VEGFR-3–treated tumors also lacked lymphatic vessels. These results suggest that the VEGFR-3 pathway contributes to tumor angiogenesis and that effective inhibition of tumor progression may require the inhibition of multiple angiogenic targets. [Cancer Res 2007;67(2):593–9]




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
E.-S. Chung, S. K. Chauhan, Y. Jin, S. Nakao, A. Hafezi-Moghadam, N. van Rooijen, Q. Zhang, L. Chen, and R. Dana
Contribution of Macrophages to Angiogenesis Induced by Vascular Endothelial Growth Factor Receptor-3-Specific Ligands
Am. J. Pathol., November 1, 2009; 175(5): 1984 - 1992.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. C. Roman, J. M. Carvajal-Gonzalez, E. M. Rico-Leo, and P. M. Fernandez-Salguero
Dioxin Receptor Deficiency Impairs Angiogenesis by a Mechanism Involving VEGF-A Depletion in the Endothelium and Transforming Growth Factor-{beta} Overexpression in the Stroma
J. Biol. Chem., September 11, 2009; 284(37): 25135 - 25148.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. P. Morelli, A. M. Brown, T. M. Pitts, J. J. Tentler, F. Ciardiello, A. Ryan, J. M. Jurgensmeier, and S. G. Eckhardt
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines
Mol. Cancer Ther., September 1, 2009; 8(9): 2546 - 2558.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. C. Douglas, H. Tang, R. Gomez, B. Pytowski, D. J. Hicklin, C. M. Sauer, J. Kitajewski, M. V. Sauer, and R. C. Zimmermann
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Functions to Promote Uterine Decidual Angiogenesis during Early Pregnancy in the Mouse
Endocrinology, August 1, 2009; 150(8): 3845 - 3854.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Anisimov, A. Alitalo, P. Korpisalo, J. Soronen, S. Kaijalainen, V.-M. Leppanen, M. Jeltsch, S. Yla-Herttuala, and K. Alitalo
Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle
Circ. Res., June 5, 2009; 104(11): 1302 - 1312.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
S. KUEMMEL, A. THOMAS, S. LANDT, A. FUGER, P. SCHMID, M. KRINER, J.-U. BLOHMER, J. SEHOULI, G. SCHALLER, W. LICHTENEGGER, et al.
Circulating Vascular Endothelial Growth Factors and their Soluble Receptors in Pre-invasive, Invasive and Recurrent Cervical Cancer
Anticancer Res, February 1, 2009; 29(2): 641 - 645.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Miyazaki, N. Okada, K. Ishibashi, K. Ogata, T. Ohsawa, T. Ishiguro, H. Nakada, M. Yokoyama, M. Matsuki, H. Kato, et al.
Clinical Significance of Plasma Level of Vascular Endothelial Growth Factor-C in Patients with Colorectal Cancer
Jpn. J. Clin. Oncol., December 1, 2008; 38(12): 839 - 843.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Lohela, H. Helotera, P. Haiko, D. J. Dumont, and K. Alitalo
Transgenic Induction of Vascular Endothelial Growth Factor-C Is Strongly Angiogenic in Mouse Embryos but Leads to Persistent Lymphatic Hyperplasia in Adult Tissues
Am. J. Pathol., December 1, 2008; 173(6): 1891 - 1901.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Kodama, Y. Kitadai, M. Tanaka, T. Kuwai, S. Tanaka, N. Oue, W. Yasui, and K. Chayama
Vascular Endothelial Growth Factor C Stimulates Progression of Human Gastric Cancer via Both Autocrine and Paracrine Mechanisms
Clin. Cancer Res., November 15, 2008; 14(22): 7205 - 7214.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. D. Hu-Lowe, H. Y. Zou, M. L. Grazzini, M. E. Hallin, G. R. Wickman, K. Amundson, J. H. Chen, D. A. Rewolinski, S. Yamazaki, E. Y. Wu, et al.
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Clin. Cancer Res., November 15, 2008; 14(22): 7272 - 7283.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. M. Ellis and D. J. Hicklin
Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy
Clin. Cancer Res., October 15, 2008; 14(20): 6371 - 6375.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. B. Burton, S. J. Priceman, J. L. Sung, E. Brakenhielm, D. S. An, B. Pytowski, K. Alitalo, and L. Wu
Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
Cancer Res., October 1, 2008; 68(19): 7828 - 7837.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Ny, M. Koch, W. Vandevelde, M. Schneider, C. Fischer, A. Diez-Juan, E. Neven, I. Geudens, S. Maity, L. Moons, et al.
Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles
Blood, September 1, 2008; 112(5): 1740 - 1749.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo
The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis
Cancer Res., June 15, 2008; 68(12): 4754 - 4762.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Oka, C. Iwata, H. I. Suzuki, K. Kiyono, Y. Morishita, T. Watabe, A. Komuro, M. R. Kano, and K. Miyazono
Inhibition of endogenous TGF-{beta} signaling enhances lymphangiogenesis
Blood, May 1, 2008; 111(9): 4571 - 4579.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. P. Padera, M. Ancukiewicz, T. Hoshida, D. Fukumura, and R. K. Jain
Anti-VEGFR-3 Therapy and Lymph Node Metastasis
Cancer Res., May 15, 2007; 67(10): 5055 - 5055.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.